These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
30. Nucleotide variation in Sabin type 3 poliovirus from an Albanian infant with agammaglobulinemia and vaccine associated poliomyelitis. Foiadelli T; Savasta S; Battistone A; Kota M; Passera C; Fiore S; Bino S; Amato C; Lozza A; Marseglia GL; Fiore L BMC Infect Dis; 2016 Jun; 16():277. PubMed ID: 27287521 [TBL] [Abstract][Full Text] [Related]
31. Advances in vaccine stability monitoring technology. Zweig SE Vaccine; 2006 Aug; 24(33-34):5977-85. PubMed ID: 16759766 [TBL] [Abstract][Full Text] [Related]
32. [Study on the failure time of the vaccine vial monitor used for oral poliovirus vaccine at 25 ℃ and 37 ℃]. Wen CK; Zhou CN; Jiang L; Chen ZG Zhonghua Yu Fang Yi Xue Za Zhi; 2017 Mar; 51(3):248-251. PubMed ID: 28260340 [No Abstract] [Full Text] [Related]
35. [Genetic recombination in vaccine poliovirus: comparative study in strains excreted in course of vaccination by oral poliovirus vaccine and circulating strains]. Haddad-Boubaker S; Ould-Mohamed-Abdallah MV; Ben-Yahia A; Triki H Pathol Biol (Paris); 2010 Dec; 58(6):420-5. PubMed ID: 19299091 [TBL] [Abstract][Full Text] [Related]
36. CURRENT STATUS OF MEASLES AND ORAL POLIOVIRUS VACCINES. MACLEOD DR Can Med Assoc J; 1964 Nov; 91(21):1118-22. PubMed ID: 14229761 [TBL] [Abstract][Full Text] [Related]
37. The temperature sensitivity of the Sabin type 3 vaccine strain of poliovirus: molecular and structural effects of a mutation in the capsid protein VP3. Minor PD; Dunn G; Evans DM; Magrath DI; John A; Howlett J; Phillips A; Westrop G; Wareham K; Almond JW J Gen Virol; 1989 May; 70 ( Pt 5)():1117-23. PubMed ID: 2543771 [TBL] [Abstract][Full Text] [Related]
38. Are childhood immunization programmes in Australia at risk? Investigation of the cold chain in the Northern Territory. Miller NC; Harris MF Bull World Health Organ; 1994; 72(3):401-8. PubMed ID: 8062398 [TBL] [Abstract][Full Text] [Related]
39. The molecular biology of poliovaccines. Minor PD J Gen Virol; 1992 Dec; 73 ( Pt 12)():3065-77. PubMed ID: 1335021 [No Abstract] [Full Text] [Related]
40. Evaluating the value proposition for improving vaccine thermostability to increase vaccine impact in low and middle-income countries. Karp CL; Lans D; Esparza J; Edson EB; Owen KE; Wilson CB; Heaton PM; Levine OS; Rao R Vaccine; 2015 Jul; 33(30):3471-9. PubMed ID: 26055297 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]